Multicenter, Single-arm Open-label Extension Study to Assess Long term Safety and Efficacy of Current or Prior Treatment with Denosumab in Children/Young Adults with Osteogenesis Imperfecta
Phase of Trial: Phase III
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Osteogenesis imperfecta
- Focus Adverse reactions
- Sponsors Amgen
- 31 Jul 2019 Planned End Date changed from 25 Sep 2023 to 15 Mar 2024.
- 31 Jul 2019 Planned primary completion date changed from 25 Sep 2023 to 15 Mar 2024.
- 26 Jul 2018 New trial record